...Eboni Goodrich Research Paper 1 Project 3; (400 hours) February 17th, 2014 Tennessee Academy of Cosmetology Michele Byers didn't have any skin problems. She just wanted to do something nice for herself as she approached her 50th birthday. Byers went to an at-home esthetician for microdermabrasion, a nonsurgical procedure that polishes away dead skin. After a session, bumps started to appear on Byers' face. Her cheeks were covered in indentations. "It looked like a railroad track on my forehead and nose," says Byers of Castro Valley, Calif. "Here I was trying to do something nice for myself and I ended up looking worse than I ever had in my life." Contrary to popular belief, darker skin is not tougher; in fact, while extra melanin does have its benefits - sun protection and slowed signs of aging - it makes the skin more sensitive and vulnerable to injury. The side effects are common for people with darker skin. Most skin care is only marketed to white people (lacking tone), not even Asians, Hispanics and darker-skinned Europeans. Education of the skin is geared to white skin, and it's still not considered to be a prestigious career here in the United States as with beauty advisers in Europe. If the skin is darker it is prone to scarring and hyper-pigmentation, so we have to be more careful with skin of color. Latin, Asian, Indian, Mediterranean or African-American descents skin requires special skin care. Even acne or laser hair removal should be handled differently on...
Words: 829 - Pages: 4
...School of Communication and Creative Arts Department of Communication & Media Studies Subject Code: MBAM 003 Subject Name: Media Planning & Buying Group Assignment May 2015 Semester Group Members: 1) Yew Chi Yin (0103082) 2) Liew Kah Chun (0110111) 3) Nor Azeriah Aida Bt Awang (0107003) 4) Kwang Yuk Ching (0100919) 5) Shawn Khoo Kay Keong (0106679) 6) Chong Po Yeng (0103069) Assignment Due Date: 27th July 2015 TABLE OF CONTENTS TITLE PAGE …………………………………………………………………...…….I 1 BACKGROUND Current Skincare Trend in Malaysia…………………………………...….1 Latest Value Perceptions toward Skincare…………………………..…....3 Top 4 Trends in Skin Care in Malaysia……………………….……..……4 Brief about L’Oréal Paris……………………………………..……….…..5 Current Direction of L’Oréal………………………………..……….……6 Skincare Products under L’Oréal Paris………………………………...….7 Prospective Consumers……………………………………………..….….7 Competitor Analysis…………………………………………………....….8 2 MARKETING OBJECTIVE …………………………………………….…11 3 ADVERTISING OBJECTIVE…………………………………………..…..11 4 TARGET AUDIENCE ANALYSIS AND RECOMMENDATION……..…12 5 SWOT ANALYSIS ……………………………………………………..…..14 6 MEDIA OBJECTIVE………………………………………………..………16 7 MEDIA STRATEGY………………………………………………..………16 8 MEDIA MIX……………………………………………………...…...…….17 9 MEDIA PLAN Thematic Media Plan………………………………………….…….20 Event Media Plan…………………………………………...…..…...25 Media Flowchart…………………………………………………….28 II 10 CONCLUSION.……………………………………………………..……...
Words: 7242 - Pages: 29
...CONTE N T S CHAI R M A N ’ S LETTE R DEAR SH AREH OL DERS FY2012 has been a good year for your Company. The key financial results were: ¥ Consolidated revenues increased by 30% to Rs. 96.7 billion in FY2012. ¥ Earnings before interest, taxes, depreciation and amortization (EBITDA)1 rose by 55% to Rs. 25.4 billion. ¥ Profit after Tax (PAT)2 grew by 45% to Rs. 15.3 billion. ¥ Diluted Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the biosimilars business continues along its impressive growth path. In my letter to you last year, I had discussed the critical importance of developing biosimilars in the years to come. I am happy to note that your Company’s global biosimilars business grew by 45% over last year and recorded sales of USD 26 million. Today, the biosimilars portfolio of Dr. Reddy’s constitutes (i) filgrastim, (ii) peg-filgrastim, (iii) rituximab and (iv) darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. These are helping to treat patients suffering from cancer — and at prices that...
Words: 128176 - Pages: 513
